A prospective, multicenter validation study of a prognostic index composed of S-phase fraction, progesterone receptor status, and tumour size predicts survival in node-negative breast cancer patients: NNBC, the node-negative breast cancer trial

Annals of Oncology

Volumn 24, Issue 9, 2013, Pages 2284-2291

  Klintman, M ^a,b   Nilsson, F ^c   Bendahl, P O ^a   Ferno M ^a   Liljegren, G ^d   Emdin, S ^c   Malmstrom P ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^d ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Breast cancer; Prognosis; Proliferation; Prospective; S phase; Validation

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CELL CYCLE S PHASE; CELL PROLIFERATION; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NODE NEGATIVE BREAST CANCER; PARTIAL MASTECTOMY; PREDICTION; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SURVIVAL TIME; TUMOR VOLUME; VALIDATION STUDY;

BREAST CANCER; PROGNOSIS; PROLIFERATION; PROSPECTIVE; S-PHASE; VALIDATION;

BREAST NEOPLASMS; CELL PROLIFERATION; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; MITOTIC INDEX; PROSPECTIVE STUDIES; RECEPTORS, PROGESTERONE; S PHASE; SURVIVAL; TUMOR MARKERS, BIOLOGICAL;

EID: 84883346419     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt186     Document Type: Article

References (36)

1. Goldhirsch A, Wood WC, Coates AS et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-1747.
2. Wirapati P, Sotiriou C, Kunkel S et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008; 10: R65.
3. Harris L, Fritsche H, Mennel R et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25: 5287-5312.
4. Baak JP, van Diest PJ, Voorhorst FJ et al. Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years. J Clin Oncol 2005; 23: 5993-6001.
5. Amadori D, Nanni O, Marangolo M et al. Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with nodenegative, rapidly proliferating breast cancer: a randomized multicenter study. J Clin Oncol 2000; 18: 3125-3134.
6. Paradiso A, Schittulli F, Cellamare G et al. Randomized clinical trial of adjuvant fluorouracil, epirubicin, and cyclophosphamide chemotherapy for patients with fast-proliferating, node-negative breast cancer. J Clin Oncol 2001; 19: 3929-3937.
7. Ewers SB, Attewell R, Baldetorp B et al. Prognostic potential of flow cytometric S-phase and ploidy prospectively determined in primary breast carcinomas. Breast Cancer Res Treat 1992; 20: 93-108.
8. Michels JJ, Marnay J, Delozier T et al. Proliferative activity in primary breast carcinomas is a salient prognostic factor. Cancer 2004; 100: 455-464.
9. Hayes DF, Bast RC, Desch CE et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996; 88: 1456-1466.
10. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009; 101: 1446-1452.
11. Colozza M, Azambuja E, Cardoso F et al. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?. Ann Oncol 2005; 16: 1723-1739.
12. Janicke F, Prechtl A, Thomssen C et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinasetype plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001; 93: 913-920.
13. Braun S, Vogl FD, Naume B et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005; 353: 793-802.
14. Sigurdsson H, Baldetorp B, Borg A et al. Indicators of prognosis in node-negative breast cancer. N Engl J Med 1990; 322: 1045-1053.
15. Ferno M, Bendahl PO, Brisfors A et al. Intra- and inter-laboratory reproducibility of estrogen and progesterone receptor enzyme immunoassay in breast cancer cytosol samples-a Swedish multicenter study. Swedish Society of Cancer Study Group. Acta Oncol 1997; 36: 793-798.
16. Ferno M, Stal O, Baldetorp B et al. Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels. South Sweden Breast Cancer Group, and South-East Sweden Breast Cancer Group. Breast Cancer Res Treat 2000; 59: 69-76.
17. Baldetorp B, Bendahl PO, Ferno M et al. Improved DNA flow cytometric, DNA ploidy, and S-phase reproducibility between 15 laboratories in analysis of breast cancer using generalized guidelines. Cytometry A 2003; 56: 1-7.
18. Kallioniemi OP, Blanco G, Alavaikko M et al. Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S-phase fraction. A proposed classification of DNA histograms in breast cancer. Cancer 1988; 62: 2183-2190.
19. Sigurdsson H, Baldetorp B, Borg A et al. Flow cytometry in primary breast cancer: improving the prognostic value of the fraction of cells in the S-phase by optimal categorisation of cut-offlevels. Br J Cancer 1990; 62: 786-790.
20. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957; 11: 359-377.
21. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multistate models. Stat Med 2007; 26: 2389-2430.
22. Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
23. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika 1982; 69: 239-241.
24. Cardoso F, Piccart-Gebhart M, Van't Veer L et al. The MINDACT trial: the first prospective clinical validation of a genomic tool. Mol Oncol 2007; 1: 246-251.
25. Rutgers E, Piccart-Gebhart MJ, Bogaerts J et al. The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase. Eur J Cancer 2011; 47: 2742-2749.
26. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005; 23: 7212-7220.
27. de Azambuja E, Cardoso F, de Castro G, Jr. et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 2007; 96: 1504-1513.
28. Duigou F, Herlin P, Marnay J et al. Variation of flow cytometric DNA measurement in 1,485 primary breast carcinomas according to guidelines for DNA histogram interpretation. Cytometry 2000; 42: 35-42.
29. Shankey TV, Rabinovitch PS, Bagwell B et al. Guidelines for implementation of clinical DNA cytometry. International Society for Analytical Cytology. Cytometry 1993; 14: 472-477.
30. Klintman M, Bendahl PO, Grabau D et al. The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer. Mod Pathol 2010; 23: 251-259.
31. Jung SY, Han W, Lee JW et al. Ki-67 expression gives additional prognostic information on St. Gallen 2007 and Adjuvant! Online risk categories in early breast cancer. Ann Surg Oncol 2009; 16: 1112-1121.
32. Davies C, Godwin J, Gray R et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378: 771-784.
33. Clark GM, McGuire WL, Hubay CA et al. The importance of estrogen and progesterone receptor in primary breast cancer. Prog Clin Biol Res 1983; 132E: 183-190.
34. Liu S, Chia SK, Mehl E et al. Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients. Breast Cancer Res Treat 2010; 119: 53-61.
35. Rakha EA, Reis-Filho JS, Ellis IO. Combinatorial biomarker expression in breast cancer. Breast Cancer Res Treat 2010; 120: 293-308.
36. Boyages J, Chua B, Taylor R et al. Use of the St Gallen classification for patients with node-negative breast cancer may lead to overuse of adjuvant chemotherapy. Br J Surg 2002; 89: 789-796.